The Food and Drug Administration issued its 2016-2025 Strategic Plan for its Foods and Veterinary Medicine Program (here). The FDA set four broad goals involving food safety, nutrition, protection of human and animal health and "organizational excellence." The agency will work to modernize its food safety efforts by "broadening interaction with foreign partners and increasing oversight of importers, who will have more responsibility for the safety of imported foods," said Stephen Ostroff, deputy commissioner for Foods and Veterinary Medicine, and Howard Sklamberg, deputy commissioner for Global Regulatory Operations and Policy, in a letter that accompanied the strategic plan (here). Otherwise, the plan includes few mentions of import-related efforts. The agency is also seeking public comments on the plan, it said in a July 14 Federal Register notice (here).
On July 12 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 11 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 8 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 7, the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Food and Drug Administration issued its weekly Enforcement Report for July 6 that lists the status of recalls and field corrections for food, drugs, biologics and devices (here). The report covers both domestic and foreign firms.
On July 6, the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 5, the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Food and Drug Administration ended its increased surveillance procedures for "FDA-regulated products imported from the industrial center Binhai New Area in Tianjin, China, and Xiditou Township of Beichen District in Tianjin, China," CBP said in a CSMS message (here). "FDA has returned to routine surveillance of FDA-regulated products from this region." The FDA increased the surveillance after a major explosion at a Chinese port caused chemical contamination risks for goods from that area (see 1512230069).
On July 1, the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of: